RE:RE:RE:RE:RE:RE:RE:RE:TRT POST FROM THE OTHER BOARD RE AGM THANKS TRTFact of the matter is regardless if rvx decided to go on there own to finance phase2c that in 2 years they would still have to partner with bp to get through a phase 3 trial. One might say that a successful phase 2c would guarantee a buyout would misguided as I feel bp would still want some guarantees of FDA approval before a complete buyout. Thus a cvr might a great alternative that mitigates the risk to buyer and seller. It's a good fit